31 August 2018
Visiongain’s study predicts expansion in the bioinformatics market Report will continue until 2026, especially in the genomics sector, which will remain dominant. The chemoinformatics and drug discovery sector will have the highest revenue growth rate during this period, as the use of bioinformatics in personalised medicine increases. In 2015, the genomics submarket formed the most lucrative part of that industry, accounting for 48.6% of the overall world market. As the bioinformatics market grows, this segment will continue to dominate.
The report’s author said: “The bioinformatics market has strong potential, with many innovative software platforms that can offer analysis of not only genomic data but proteomic, transcriptomic and chemoinformatic data. With so many sources of data, a company that can offer integrated analysis and interpretation will have a competitive edge. Researchers will also be looking to bioinformatics companies to provide security and flexibility such as cloud-based bioinformatics to facilitate collaborations and enable data access from anywhere. An important restraint on growth of the market will be a shortage of trained expertise; over our forecast period the success of the market will depend on remedying this deficit. The bioinformatics market will continue to expand, bolstered by governmental investment and lower costs of sequencing, as the trend towards personalised medicine ensures that demand stays strong.”
Visiongain’s new investigation shows bioinformatic revenue predictions to 2026 at overall world market, submarket and regional level. First it forecasts the following segments of the bioinformatics market to 2026:
• Genomics • Metabolomics • Proteomics • Transcriptomics • Chemoinformatics and drug discovery • Other applications.
That work also analyses leading national markets for those informatics tools, providing revenue forecasts to 2026 for these countries and regions:
• United States • European Union • Japan • China • India • Rest of the world.
In addition visiongain’s survey examines leading bioinformatic companies. That study discusses mergers and acquisitions, collaborations and developments, also showing a research interview. The report highlights organisations such as these:
• QIAGEN • Illumina • Thermo Fisher Scientific • 3rd Millennium • DNASTAR • DNAnexus • Compugen.
Bioinformatics Market Analysis, Developments and Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio covers pharmaceuticals, medical devices, diagnostics and outsourced services, including contract research, manufacturing and selling. Each year new and updated studies appear.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.